[Recent trend of infection caused by Pseudomonas aeruginosa in patients with hematologic disorders].
Funada
H
H
Protected Environment Unit, Kanazawa University School of Medicine.
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000382:microbiology* / Q000628:therapy; D006801:Humans; D007769:Lactams; D016173:Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D011379:Prognosis; D011552:Pseudomonas Infections; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D007769:Lactams; D016179:Granulocyte Colony-Stimulating Factor; D016173:Macrophage Colony-Stimulating Factor